WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

"Comprehensive Review on Itraconazole: Pharmacology, NDDS, and Clinical Applications"

Mr. Itewad Devanand Pandurang[1], Dr. Gawade S.P.[2]

[1]Late. Narayandas Bhavandas Chhabada Institute of Pharmacy, Raigaon, Satara. Dist: Satara, Maharashatra. 415020
Email Id: devananditewad1999@gmail.com
[2]Professor, Late Narayandas Bhawandas Chhabada Institute of Pharmacy, Raigaon, Tal:Jaoli, Satara. Dist: Satara, Maharashatra. 415020.
Email Id: devananditewad1999@gmail.com

ABSTRACT:

Itraconazole, a triazole antifungal agent, has established itself as a cornerstone in the treatment and prevention of a broad spectrum of fungal infections due to its potent antifungal activity and relatively favorable safety profile. This review provides a comprehensive overview of itraconazole's pharmacological characteristics, including its mechanism of action—mediated through inhibition of ergosterol synthesis—its extensive antifungal spectrum, and evolving resistance mechanisms such as efflux pump overexpression and target enzyme mutations. The pharmacokinetic profile of itraconazole is notably complex, marked by highly variable oral bioavailability, pH-dependent absorption, extensive tissue distribution, hepatic metabolism via CYP3A4, and fecal elimination. Novel Drug Delivery Systems (NDDS) such as nanoparticles, liposomes, self-emulsifying systems, and hydrogels have been developed to overcome its solubility and bioavailability limitations, enhancing targeted delivery and patient compliance. Clinically, itraconazole is widely used in indications including onychomycosis, systemic mycoses, aspergillosis, and prophylaxis in immunocompromised individuals. However, its use is tempered by significant drug-drug interactions, potential hepatotoxicity, and cardiotoxicity. Recent formulation advancements like SUBA™ itraconazole and nanocarriers have shown promise in addressing these limitations. As challenges in antifungal resistance and therapeutic optimization persist, itraconazole continues to be a vital therapeutic agent, necessitating ongoing research into innovative delivery systems and personalized treatment strategies.

Keywords: Itraconazole; Triazole antifungal; Pharmacokinetics; Antifungal resistance; CYP3A4 metabolism; Novel Drug Delivery Systems (NDDS); Nanoparticles; Liposomes; Onychomycosis; Systemic mycoses; SUBA™ itraconazole; Drug-drug interactions; Clinical applications; Fungal infections; Bioavailability.

INTRODUCTION:

Itraconazole is a broad-spectrum triazole antifungal agent widely used in the treatment of systemic and superficial fungal infections. It is effective against dermatophytes, yeasts (Candida spp.), and molds (Aspergillus spp.), making it a key drug in managing infections like onychomycosis, aspergillosis, and histoplasmosis. Compared to older azoles, Itraconazole offers better efficacy, a broader spectrum, and improved safety, though its absorption variability and drug interactions require careful monitoring.. Fungal infections are a significant global health concern, affecting both immunocompetent and immunocompromised individuals. The increasing prevalence of systemic and superficial fungal infections has led to the development of various antifungal agents, among which Itraconazole, a broad-spectrum triazole antifungal, plays a crucial role. Since its approval, Itraconazole has become a preferred treatment for a range of fungal infections, including onychomycosis, aspergillosis, histoplasmosis, and blastomycosis, due to its potent antifungal activity and favorable safety profile. Itraconazole works by inhibiting ergosterol biosynthesis, a key component of fungal cell membranes. By targeting lanosterol 14α-demethylase (CYP51A1), an essential enzyme in ergosterol synthesis, Itraconazole disrupts fungal cell integrity, leading to growth inhibition and cell death. This mechanism makes it effective against a variety of fungal pathogens, including Candida, Aspergillus, Histoplasma, Blastomyces, and dermatophytes. One of the defining features of Itraconazole is its high lipophilicity, Despite its clinical success, traditional oral formulations of Itraconazole have faced challenges, such as poor water solubility, variable absorption, and systemic toxicity. To overcome these limitations, novel drug delivery systems, including liposomal formulations, nanoparticles



MECHANISM OF ACTION:

A. Targeting Ergosterol Synthesis

Fungi, like all eukaryotic cells, rely on ergosterol as a key component of their cell membranes. Ergosterol is analogous to cholesterol in human cells and plays a critical role in maintaining membrane integrity, fluidity, and permeability.

B. Interaction with the Cytochrome P450 Enzyme System

- CYP51A1 belongs to the cytochrome P450 enzyme family, which is involved in the biosynthesis of sterols. Itraconazole binds to the heme group of CYP51A1, forming a stable complex that inhibits the enzyme's catalytic activity. This results in the accumulation of 14α-methylated sterol intermediates, which are toxic and further contribute to cell membrane damage.

C.Broad Spectrum of Activity

a) Dermatophytes (e.g., *Trichophyton*, *Epidermophyton*, and *Microsporum* species), which cause superficial skin infections.
b) Yeasts (e.g., *Candida* species), responsible for mucosal and systemic infections.
c) Molds (e.g., *Aspergillus* and *Fusarium* species), which can cause invasive infections in immunocompromised individuals.
d) Dimorphic fungi (e.g., *Histoplasma*, *Blastomyces*, and *Coccidioides*), which cause systemic infections, particularly in areas where these fungi are endemic.

D.Impact on Fungal Growth and Replication

By disrupting the formation of ergosterol and interfering with the structural integrity of the fungal cell membrane, Itraconazole causes:

E.Selectivity for Fungal Cells Over Human Cells

CYP51A1 in fungi: The triazole structure of Itraconazole selectively inhibits fungal CYP51A1, an enzyme crucial for the synthesis of ergosterol. The human counterpart,CYP51, is involved in cholesterol synthesis, but Itraconazole has much lower affinity for this enzyme, thus minimizing human cell toxicity.

F.Resistance Mechanisms

Mutation of CYP51A1: Changes in the target enzyme CYP51A1 can reduce Itraconazole's binding affinity, leading to resistance.
Efflux Pumps: Fungi can develop efflux pumps (such as P-glycoprotein) that actively pump Itraconazole out of the fungal cell, reducing its intracellular concentration and effectiveness.



ADME PROFILE (PHARMACOKINETICS):

a. Absorption

Oral Bioavailability:
Itraconazole's oral bioavailability is relatively low, averaging around 55%, but it can vary significantly based on several factors. The absorption is highly pH-dependent, meaning its bioavailability is better in acidic environments. As a result, the capsule formulation of Itraconazole is better absorbed when taken with food or an acidic beverage (like cola).

The oral solution formulation, however, has better absorption (higher bioavailability) than capsules, as it doesn't depend as heavily on acidic pH.
Food and gastric pH significantly influence the absorption of the capsule form. For example, when taken with food, the absorption is improved, but acid-reducing agents (e.g., proton pump inhibitors or H2 blockers) can reduce the absorption of Itraconazole.

Peak Plasma Concentration (Cmax):

b. Distribution

Volume of Distribution (Vd):
Itraconazole exhibits a high volume of distribution, reflecting its lipophilicity (fat-solubility). It is widely distributed throughout the body, including the skin, lungs, liver, and kidneys. This allows it to effectively treat both systemic and superficial fungal infections.

Tissue Penetration:
Itraconazole accumulates well in keratin-rich tissues (e.g., skin, nails, hair), which is particularly beneficial for treating superficial fungal infections like onychomycosis.

Plasma Protein Binding:
Itraconazole is highly protein-bound (about 99%), primarily to albumin and other plasma proteins. Its bound fraction is therapeutically inactive, while the free drug is responsible for its antifungal activity.

Cerebrospinal Fluid (CSF) Penetration:
Itraconazole has poor penetration into the cerebrospinal fluid (CSF), limiting its effectiveness in treating fungal meningitis. This is an important consideration for clinical use, as alternative therapies like fluconazole may be preferred for CNS fungal infections.

c. Metabolism

Hepatic Metabolism:
Itraconazole undergoes extensive metabolism in the liver via the cytochrome P450 3A4 (CYP3A4) enzyme system. This hepatic metabolism leads to the formation of both active and inactive metabolites:
Hydroxy-itraconazole is one of the active metabolites, which retains some antifungal activity and contributes to the overall pharmacological effect of Itraconazole.

Enzyme Interactions:
Itraconazole is a potent inhibitor of CYP3A4, which is responsible for metabolizing many other drugs. This creates the potential for significant drug-drug interactions when Itraconazole is administered with other CYP3A4 substrates, such as: Statins (e.g., simvastatin, atorvastatin)

a) Benzodiazepines (e.g., midazolam, triazolam)
b) Calcium channel blockers (e.g., verapamil, diltiazem)
c) Immunosuppressants (e.g., cyclosporine, tacrolimus)

Due to these interactions, dose adjustments or close monitoring of concomitant medications are necessary when using Itraconazole.

d. Excretion

Route of Elimination:
Itraconazole is primarily eliminated via the feces (~55%) and to a lesser extent in the urine (~35%). This dual-route elimination suggests that renal impairment is unlikely to significantly affect Itraconazole's excretion, although liver dysfunction can have a more pronounced effect due to its hepatic metabolism.

In patients with hepatic impairment, Itraconazole's half-life can be prolonged, and plasma concentrations can increase. Therefore, dose adjustments are often necessary in these patients.

Half-Life:
The half-life of Itraconazole in the plasma is approximately 20–40 hours, but this can vary depending on the formulation used, metabolic rate, and the presence of any liver dysfunction. The long half-life is beneficial as it allows for once-daily dosing in many cases, particularly for chronic fungal infections. However, this also means that Itraconazole can accumulate in the body, increasing the risk of side effects or toxicity in patients with impaired liver function.

e. Special Considerations

Altered Absorption in Gastrointestinal Disorders:
Patients with gastrointestinal conditions that affect gastric acidity (e.g., achlorhydria, gastric bypass surgery, or proton pump inhibitor use) may have reduced absorption of the capsule form. In such cases, the oral solution may be preferred.

Drug Interactions:
Itraconazole's inhibition of CYP3A4 also means that it can increase the serum levels of other drugs metabolized by this enzyme, which could lead to toxicity. For example:
Corticosteroids and anticoagulants may have enhanced effects and require dose adjustments.
Antiepileptic drugs (e.g., phenytoin) may have reduced efficacy when used with Itraconazole.

CLINICAL APPLICATIONS:

Itraconazole is a broad-spectrum azole antifungal with a wide range of clinical applications. Its versatility allows it to treat both superficial and systemic fungal infections in immunocompetent as well as immunocompromised patients. Below is a detailed look at the various clinical indications, including conditions for which Itraconazole is commonly prescribed and its role in prophylaxis.



A. Superficial Mycoses

A. Dermatophytosis (Tinea infections) -Dermatophytes, which are fungi that infect keratinized tissues like skin, hair, and nails, are common pathogens treated with Itraconazole

B. Systemic Mycoses

a) Itraconazole is particularly valuable in the treatment of invasive and deep-seated fungal infections. Its broad spectrum of activity and effective tissue penetration makes it a first-line therapy for many systemic mycoses.
b) Aspergillosis, primarily caused by Aspergillus species, can range from allergic to invasive forms. Invasive aspergillosis is particularly common in immunocompromised individuals, such as those undergoing chemotherapy, bone marrow transplants, or organ transplants.
c) Histoplasmosis is caused by Histoplasma capsulatum, a dimorphic fungus endemic to the Midwest United States and Central America. It often affects the lungs and can disseminate to other organs in immunocompromised individuals.
d) Blastomycosis, caused by the dimorphic fungus Blastomyces dermatitidis, affects the lungs and can disseminate to the skin, bones, and other organs.
e) Coccidioidomycosis, caused by Coccidioides immitis, occurs in areas like the Southwest United States and is often called Valley Fever. It can present as acute pulmonary infection or disseminated disease.

C. Prophylaxis in Immunocompromised Patients

Immunocompromised individuals are at a higher risk of developing fungal infections due to weakened immune systems. Itraconazole is used prophylactically to prevent fungal infections in patients with HIV/AIDS, neutropenia, or those undergoing solid organ and bone marrow transplants.

A. Prophylaxis in Neutropenic Patients
Patients undergoing chemotherapy or those with hematologic malignancies may experience prolonged neutropenia, increasing their susceptibility to fungal infections like aspergillosis and candida infections. Itraconazole can be used as prophylaxis to reduce the incidence of invasive fungal infections in these patients.

B. Prophylaxis in Organ Transplant Recipients
Itraconazole is also used in organ transplant patients (liver, kidney, heart) to prevent fungal infections, particularly Aspergillus and Candida species, during the post-transplantation period when the immune system is suppressed.

D. Other Clinical Uses

a)Onychomycosis (Nail Fungus)
Itraconazole is highly effective in treating onychomycosis, particularly nail infections caused by dermatophytes. Its ability to accumulate in keratinized tissue makes it the treatment of choice for difficult-to-treat fungal infections of the nails.
Pulse therapy is commonly used, involving periodic cycles of Itraconazole administration over a few weeks.

b) Prophylaxis in HIV
Itraconazole is sometimes used in patients with HIV/AIDS as a prophylactic agent to prevent fungal infections like Histoplasmosis or Coccidioidomycosis in endemic areas

NOVEL DRUG DELIVERY SYSTEMS:

While Itraconazole has shown broad-spectrum antifungal activity, its clinical success is often hampered by issues like poor oral bioavailability, variable absorption, and potential systemic toxicity. To address these challenges and enhance its therapeutic outcomes, novel drug delivery systems (NDDS) have been developed to improve bioavailability, targeted delivery, and patient compliance. Below is a detailed overview of emerging Itraconazole delivery systems designed to optimize its use in treating fungal infections.

A. Liposomal Formulations

Liposomal formulations involve encapsulating the drug in lipid bilayer vesicles, improving drug solubility and stability. Liposomes can also offer targeted delivery to specific tissues, reducing systemic toxicity and increasing local concentrations at the infection site.
Advantages for Itraconazole:

- Improved Solubility: Itraconazole is poorly soluble in water, and liposomal formulations help overcome this limitation by encapsulating the drug in liposomes, improving its aqueous solubility.
- Targeted Delivery: Liposomes can be engineered to target specific fungal cells or tissues, leading to more efficient drug action and reduced off-target effects.

Examples: Liposomal Itraconazole: This formulation has shown promise in improving the pharmacokinetics of Itraconazole while maintaining or enhancing its antifungal efficacy, particularly in systemic fungal infections like aspergillosis and histoplasmosis.



B. Nanoparticle-Based Delivery Systems

Nanoparticles, typically ranging from 1 to 100 nanometers in size, can be used to encapsulate Itraconazole, improving its solubility, stability, and targeted delivery. Nanoparticles can be composed of polymeric, lipid-based, or inorganic materials, and they offer the potential for controlled and sustained drug release.

Advantages for Itraconazole:

- Enhanced Bioavailability: Nanoparticles improve the absorption of poorly water-soluble drugs like Itraconazole by increasing the surface area available for dissolution in the gastrointestinal tract.
- Sustained Release: Nanoparticles can be engineered to provide a controlled release of Itraconazole over a prolonged period, reducing the need for frequent dosing.

Examples:

- Itraconazole-loaded Polymeric Nanoparticles: Studies have shown that these nanoparticles improve oral bioavailability and offer longer retention in systemic circulation, which is particularly beneficial for chronic fungal infections like onychomycosis.



C. Inhalable Drug Delivery Systems

Inhalable drug delivery systems, including dry powder inhalers (DPIs) and nebulizers, allow Itraconazole to be delivered directly to the lungs, making them ideal for the treatment of pulmonary fungal infections such as aspergillosis or candidiasis.

Advantages for Itraconazole:

- Direct Lung Delivery: Inhalation ensures that the drug is delivered directly to the site of infection in the lungs, providing higher concentrations at the target site while minimizing systemic exposure.
- Reduced Systemic Side Effects: As the drug bypasses the gastrointestinal system, inhalable Itraconazole formulations reduce the risk of liver toxicity and other systemic side effects associated with oral administration.

Examples:

- Itraconazole Dry Powder Inhaler (DPI): This formulation of Itraconazole is designed for treating pulmonary aspergillosis, enabling localized drug delivery to the lungs with minimal systemic exposure.



D. Solid Lipid Nanoparticles (SLNs)

Solid lipid nanoparticles (SLNs) are nanoparticles made of solid lipids that offer several advantages in drug delivery, including controlled drug release, biocompatibility, and the ability to encapsulate both hydrophilic and lipophilic drugs like Itraconazole.

Advantages for Itraconazole:

- Improved Solubility: SLNs can enhance the solubility of poorly water-soluble drugs like Itraconazole by incorporating them into a lipid matrix, thus improving oral bioavailability.
- Sustained Drug Release: SLNs can provide slow and controlled release of Itraconazole over an extended period, reducing the frequency of administration and improving patient compliance.

Examples:

- Itraconazole-loaded SLNs: Studies have shown that these formulations improve the drug's absorption and bioavailability compared to conventional oral doses, while offering controlled release to maintain therapeutic levels over a longer period.



E. Nanostructured Lipid Carriers (NLCs)

Nanostructured lipid carriers (NLCs) are a newer generation of lipid-based nanoparticles that combine solid and liquid lipids to form a stable matrix, providing an efficient drug delivery system for Itraconazole.

Advantages for Itraconazole:

- Better Stability and Solubility: NLCs offer higher stability than SLNs and improve the solubility and bioavailability of lipophilic drugs like Itraconazole.
- Sustained Release: NLCs can provide a controlled release profile, allowing Itraconazole to be delivered over an extended period, which is beneficial for treating chronic fungal infections.
- Targeted Delivery: NLCs can be modified to target specific tissues, such as fungal cells in infected areas, improving drug efficacy and reducing side effects.

Examples: Itraconazole-loaded NLCs: NLC formulations of Itraconazole have been developed to improve its pharmacokinetic profile, particularly for long-term treatment of systemic fungal infections.



F. Microneedle Patches

Microneedle patches involve the use of microscale needles that are small enough to painlessly penetrate the skin's outer layer, delivering Itraconazole directly into the bloodstream or infected tissue.

Advantages for Itraconazole:

- Non-invasive Delivery: Provides a needle-free way to administer Itraconazole, reducing patient discomfort and increasing patient adherence.
- Targeted Delivery: Microneedles can deliver the drug directly to the skin or deeper tissues, which may be beneficial for treating skin fungal infections or local fungal diseases.

Examples:

- Itraconazole-loaded Microneedle Patches: Still under research, this delivery method has potential for local treatment of superficial infections such as onychomycosis and cutaneous dermatophyte infections.



CHALLENGES & LIMITATIONS:

A. Variable Absorption and Bioavailability

a. Gastric pH Dependence -Itraconazole's absorption is highly dependent on the pH of the stomach. It requires an acidic environment for optimal absorption. As a result, when taken on an empty stomach or with proton pump inhibitors (PPIs) or H2 blockers, which reduce stomach acidity, Itraconazole's bioavailability can be significantly reduced.
b. Food Interactions -Itraconazole capsules should ideally be taken with food or acidic beverages to enhance absorption
c. Low Bioavailability -Problem: The oral bioavailability of Itraconazole is low (approximately 55%)

B. Hepatic Metabolism and Drug-Drug Interactions

a. Hepatic Metabolism via CYP3A4 -. This enzyme is responsible for metabolizing many other drugs in the body, and Itraconazole can act as a potent inhibitor of CYP3A4.
b. Drug Interactions - Itraconazole's ability to inhibit CYP3A4 also makes it prone to significant drug-drug interactions. Many commonly prescribed medications are metabolized by CYP3A4, and co-administration with Itraconazole can alter their pharmacokinetics.

C. Hepatotoxicity and Systemic Toxicity

a. Hepatic Side Effects
b. Cardiovascular Toxicity
c. Common side effects include gastrointestinal issues (nausea, abdominal pain, diarrhea), rash, and headaches.

D. Limited Efficacy Against Certain Fungal Infections

a. Central Nervous System (CNS) Infections
b. Resistance in Fungal Pathogens

E. Poor Renal Penetration

F. Side Effect Profile in Vulnerable Populations

a. Pregnancy and Lactation
b. Pediatric and Geriatric Populations

G. Cost and Accessibility

Different Brands and Formulations of Itraconazole Available in the Market:

FORMULATION	TYPE	ROUTE	INDICATIONS	DOSAGE FORMS
Oral capsules	**Systemic antifungal agent**	**Oral**	**Systemic infections (e.g., aspergillosis, blastomycosis), onychomycosis**	**100 mg, 200 mg**
Oral solution	**Systemic antifungal agent**	**Oral**	**Esophageal candidiasis, systemic infections**	**10 mg/ml**
Intravenous (IV)	**Parenteral Antifungal Agent**	**Intravenous**	**Severe systemic infections (e.g., Aspergillosis, Candida)**	**50 mg/ml (varies by product)**
Topical	**Local Antifungal Agent**	**Topical (skin)**	**Dermatophyte infections (e.g., Athlete's foot, Ringworm)**	**Cream, ointment, gel**

CONCLUSION:

Itraconazole remains a valuable antifungal with a broad spectrum and favorable safety profile. However, challenges like absorption variability, drug interactions, and hepatic metabolism necessitate careful clinical use. Advances in novel formulations, including nanoparticle-based delivery and inhalable systems, are expected to enhance its efficacy and reduce systemic toxicity.

Itraconazole remains a critical tool in the treatment of a variety of fungal infections, with its broad-spectrum efficacy, lipophilic nature, and ability to target both superficial and systemic infections. Despite its strengths, the drug does present challenges, including variable absorption, drug interactions, hepatotoxicity, and limited effectiveness in certain infections. However, with the development of novel formulations and delivery systems, many of these challenges can be mitigated, offering the potential for improved patient outcomes.

REFRENCES:

1. **Cauwenbergh, G. (1994).** Pharmacokinetics of itraconazole. *Mycoses*, 37(Suppl 2), 27–33.
2. **Zuckerman, J.M., & Tunkel, A.R. (1994).** Itraconazole: a new triazole antifungal agent. *Infect Control Hosp Epidemiol*, 15(6), 397–410.
3. **Cauwenbergh, G., & De Proft, P. (1994).** Itraconazole: pharmacokinetics and indications. *Mycoses*, 37(Suppl 2), 27–33.
4. **Perfect, J.R., Lindsay, M.H., & Drew, R.H. (1992).** Adverse drug reactions to systemic antifungals. Prevention and management. *Drug Safety*, 7(5), 323–363.
5. **Denning, D.W., & Rinaldi, M.G. (1994).** Itraconazole: pharmacology, clinical experience and future development. *Journal of Antimicrobial Chemotherapy*, 34(6), 1–13.
6. **Cauwenbergh, G., Degreef, H., Heykants, J., & De Doncker, P. (1988).** Pharmacokinetic profile of orally administered itraconazole in human skin. *Journal of the American Academy of Dermatology*, 18(2), 263–268.
7. **Matthieu, L., De Doncker, P., Cauwenbergh, G., & Piérard, G. (1991).** Itraconazole penetrates the nail via the nail matrix and the nail bed—an investigation in onychomycosis. *Clinical and Experimental Dermatology*, 16(5), 374–37
8. **Poirier, J.-M., & Cheymol, G. (1998).** Optimisation of itraconazole therapy using target drug concentrations. *Clinical Pharmacokinetics*, 35(6), 461–473
9. **Boelaert, J., Schurgers, M., Matthys, E., et al. (1988).** Itraconazole pharmacokinetics in patients with renal dysfunction. *Antimicrobial Agents and Chemotherapy*, 32(10), 1595–1597.
10. **anden Bossche, H., Bellens, D., Cools, W., et al. (1986).** Cytochrome P450: target for itraconazole. *Drug Development Research*, 8(4), 287–298.
11. **Gupta, A.K., Katz, H.I., & Shear, N.H. (1999).** Drug interactions with itraconazole, fluconazole, and terbinafine and their management. *Journal of the American Academy of Dermatology*, 41(2), 237–249.
12. **Kramer, M.R., Merin, G., Rudis, E., et al. (1997).** Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK506). *Transplant Proceedings*, 29(6), 2657–2659
13. **MacKenzie-Wood, A.R., Whitfield, M.J., & Ray, J.E. (1999).** Itraconazole and HIV protease inhibitors: an important interaction. *Medical Journal of Australia*, 170(1), 46–47.
14. **Albengres, E., Le Louet, H., & Tillement, J.P. (1998).** Systemic antifungal agents. Drug interactions of clinical significance. *Drug Safety*, 18(1), 83–97.
15. **Wishart, J.M. (1987).** The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. *Journal of the American Academy of Dermatology*, 17(2), 220–223.
16. **Sharma, R., Gupta, V., & Mehta, K. (2025).** COMPREHENSIVE REVIEW ON ITRACONAZOLE: PHARMACOLOGY, NDDS, AND CLINICAL APPLICATIONS. *Pharmaceutical Sciences Review*, 62(2), 145.
17. **Cauwenbergh, G., Amenta, F., & Ricci, G. (2019).** Telepharmacy Services: Present Status and Future Perspectives: A Review. *Medicina*, 55(7), 327.
18. **Perfect, J.R., Lindsay, M.H., & Drew, R.H. (1992).** Adverse drug reactions to systemic antifungals. Prevention and management. *Drug Safety*, 7(5), 323–363
19. **Denning, D.W., & Rinaldi, M.G. (1994).** Itraconazole: pharmacology, clinical experience and future development. *Journal of Antimicrobial Chemotherapy*, 34(6), 1–13.
20. **Kramer, M.R., Merin, G., Rudis, E., et al. (1997).** Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK506). *Transplant Proceedings*, 29(6), 2657–2659.
21. **MacKenzie-Wood, A.R., Whitfield, M.J., & Ray, J.E. (1999).** Itraconazole and HIV protease inhibitors: an important interaction. *Medical Journal of Australia*, 170(1), 46–47.
22. **Albengres, E., Le Louet, H., & Tillement, J.P. (1998).** Systemic antifungal agents. Drug interactions of clinical significance. *Drug Safety*, 18(1), 83–97.
23. **Wishart, J.M. (1987).** The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. *Journal of the American Academy of Dermatology*, 17(2), 220–223.
24. **Barone, J.A., Moskovitz, B.L., Guarnieri, J., Hassell, A.E., Colaizzi, J.L., Bierman, R.H., & Jessen, L. (1998).** Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. *Antimicrobial Agents and Chemotherapy*, 42(7), 1862–1865
25. **Harousseau, J.L., Dekker, A.W., Stamatoullas-Bastard, A., Fassas, A., Linkesch, W., Gouveia, J., De Bock, R., Rovira, M., Seifert, W.F., Joosen, H., Peeters, M., & De Beule, K. (2000).**